Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

134 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H. Wiesemann HG, et al. Among authors: von der hardt h. Pediatr Pulmonol. 1998 Feb;25(2):88-92. doi: 10.1002/(sici)1099-0496(199802)25:2<88::aid-ppul3>;2-j. Pediatr Pulmonol. 1998. PMID: 9516091 Clinical Trial.
Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R, Michalsen H. Harms HK, et al. Among authors: von der hardt h. Pediatr Pulmonol. 1998 Sep;26(3):155-61. doi: 10.1002/(sici)1099-0496(199809)26:3<155::aid-ppul1>;2-k. Pediatr Pulmonol. 1998. PMID: 9773909 Clinical Trial.
Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
Derichs N, Mekus F, Bronsveld I, Bijman J, Veeze HJ, von der Hardt H, Tummler B, Ballmann M. Derichs N, et al. Among authors: von der hardt h. Pediatr Res. 2004 Jan;55(1):69-75. doi: 10.1203/01.PDR.0000100758.66805.CE. Epub 2003 Nov 6. Pediatr Res. 2004. PMID: 14605249
134 results